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studies for this therapeutic effect of acetylcysteine.
Methods: The initial electronic search queried both the Medline database and the
Cochrane Library for the perior of January 1996 ttrough May 2003. Furthermore a man-
ual inspection of articles published in New England Journal of Medicine, Circulation,
Journal of the American College of Cardiology was conducted for the years 1998-2002.
Bibliographies of the identified articles were searched for additional pertinent articles as
well as the bibliographies of three prominent cardiovascular textbooks. A meta-analysis
of the data meeting specific criteria for inclusion was performed.
Results: Five studies with a total of 641 patients were identified that evaluated the effect
of oral prophylactic administration of acetylcysteine on CIN in randomized controlled tri-
als vs. placebo. The baseline serum creatinine concentrations varied from 1.4+/_ 0.4 mg/
dlto 2.8+/_ 0.8 mg/dlin the five trials. Contrast dose ranged from< 80 ml to > 375 ml. Ace-
tylcysteine dosage was 400 mg or 600 mg bid started the day prior to or on the day of the
procedure and continued thereafter for two days. All patients received hydration with
0.45% normal saline or 0.9% normal saline pre and post procedure. Acetylcysteine
administration reduced the incidence of CIN (defined as a 0.5 mg/dl or a 25% increase in
creatinine concentration) from 11%-45% in the placebo group to 2%-8% in the acetylcys-
teine group. The combined risk ratio of the treated group was 0.19 with a combined 95%
confidence interval of 0.093 to 0.379 and a p-value of <0.0001.
Conclusions: Based on this meta-analysis, prophylactic administration of oral acetylcys-
teine significantly reduces the risk of CIN in patients with mild to moderate renal insuffi-
ciency.
1141-192 Genetic Variation in Cyclooxygenase-1 Associates With 
the Antiplatelet Effect of Aspirin in Stable Coronary 
Artery Disease
Aino Lepantalo, Jussi Mikkelsson, Julio Resendiz, Leena Heinonen, Pekka J. Karhunen, 
Riitta Lassila, Wihuri Research Institute, Helsinki, Finland, University of Tampere, 
Tampere, Finland
Impaired antithrombotic effect of aspirin may be a risk factor for coronary events in stable
coronary artery disease (CAD). The pharmacogenetics of the COX-1, the target of the
antithrombotic effect of aspirin, have not been studied previously. In the current series,
we have analysed platelet responses in stable CAD patients on aspirin. The platelet
responses were determined with optical aggregometry as well as PFA-100. The pheno-
types were related to patient characteristics as well as COX-1 haplotype.
We took blood samples from 101 patients with stable CAD on aspirin (100mg/day). The
antiplatelet effect of the treatment regimen was studied in whole blood with PFA-100 and
in platelet-rich plasma with turbidometric aggregations using arachidonic acid (AA)-
induced (1.5mmol/L) aggregation to identify the aspirin response. We used 170s. closure
time (CT-CEPI) for PFA-100 and aggregation slope of 10%/min for AA as predetermined
cut-off points for aspirin response.
7% (AA) and 22% (CT-CEPI) of patients were defined as poor aspirin responders. Indi-
viduals carrying the rare (20%) COX-1 haplotype had shorter mean CT-CEPI (222s., SD
81s.) compared to carriers of the common (80%) haplotype (261s., SD 67s.) (p=0.03). In
addition, platelets of individuals from the rare haplotype group showed more preserved
mean AA-induced maximal aggregation (31% +-6.5) compared to the common haplotype
(21%+-1.3) (p=0.02).
We conclude that impaired response to aspirin measured with PFA-100 and aggregome-
try is common among individuals with angiographically proven severe CAD and is associ-
ated with common genetic variation of COX-1.
1141-193 Short Burst Oral Amiodarone Improves Cardioversion 
Success Rates for Patients in Persistent Atrial 
Fibrillation
Christopher J. Boos, Eric Clark, Ranjit S. More, Eric Clark, St. Mary's Hospital, 
Portsmouth, United Kingdom
Background: Increasing efforts have been made to improve the success rates for external
direct-current cardioversion (EDC) for patients in persistent atrial fibrillation, without
exposing them to prolonged toxic side effects of antiarrhythmic treatment.
Methods: 35 patients with rate controlled persistent atrial fibrillation (>1month), listed for
EDC, were randomized to 2 groups. Group A received 4 weeks of oral amiodarone:
200mg Tds for 1 week prior to DCCV, then 200mg Tds week 2, 200mg Bd week 3 and
then 200mg daily for week 4. Group B did not receive amiodarone. The cardioversion
protocol of up to 5 synchronized shocks, was the same for the 2 groups (anterior-anterior
200J, 360J, 360J then anterior-posterior 360J and 360J).
Results: All results are expressed as mean ± standard deviation. The 2 groups, A and B
respectively, were demographically well matched: age (61.2 ± 12.3 vs. 61.6 ± 7.6 years,
p=0.96), weight (85.4 ± 8.90 vs. 85.4 ± 12.5 kg, p=1.0), left ventricular ejection fraction
(50.2 ± 13.5 % vs. 51 ± 13.0 %, p=0.9), left atrial size (4.4 ± 0.6 cm vs. 4.1 ± 0.8 cm,
p=0.55), mean duration of AF (7.2 ± 4.2 months vs. 10.2 ± 6.0 months, p=0.16), and
heart rate pre-cardioversion (90.8 ± 14.7/min vs. 88.1 ± 18.0/min, p=0.64). The initial car-
dioversion success rate was 17/17=100% for group A vs. 17/18=94% for group B, p=1.0).
There was a non-significant trend to the use of fewer shocks (1.7 ± 0.9 vs. 2.2 ± 1.4,
p=0.42) and less total shock energy (454 J ± 331.1 vs. 620J ± 497.8, p=0.42) in the ami-
odarone group. The number of patients remaining in sinus rhythm at 6 weeks and 6
months respectively was significantly higher in group A than group B (15/17=88% vs. 3/
18= 16.7%, p=<0.0001 and 11/17=65% vs. 3/18= 17%, (p=0.0016) respectively. How-
ever, by a mean follow-up of 16.2 (± 4.1) months there was only a non-significant trend to
a higher rate of sinus rhythm in the amiodarone group as compared with the control
group (8/17, 47.1% vs. 3/18, 16.7%; p=0.075).
Conclusion: For patients in persistent AF, a short course of oral amiodarone appears to
improve 6 week and 6 month sinus rhythm rates following external direct-current cardio-
version. This interesting data needs to backed up by a larger randomized study.
1141-194 Chronic Therapy With Phospodiesterase 5 Inhibitor 
Tadalafil Has a Sustained Effect on Endothelial Function
Giuseppe M. Rosano, Antonio Aversa, Cristiana Vitale, Andrea Fabbri, Massimo Fini, 
Giovanni Spera, San Raffaele Roma, Roma, Italy, University of Roma "La Sapienza", 
Roma, Italy
Erectile dysfunction (Ed) is often associated with a cluster of risk factors for coronary
artery disease and with a reduced endothelial function. Acute administration of phos-
phodiesterase-5 inhibitors (PDE5) improves endothelial function in patients with ED. Tad-
alafil is a newer PDE5 inhibitor with a long half life that allows chronic administration and
chronic therapy with Tadalafil has been suggested to be beneficial in patients with ED.
We hypothesized that chronic therapy with T may improve endothelial function in patients
with ED and increased cardiovascular risk. To this end we randomized 32 patients with
ED to receive either T 20 mg on alternate days or matching placebo (P) for 1 month. Bra-
chial artery flow-mediated dilation (FMD) was assessed at baseline, at 1 month and at 6
weeks. At 1 month FMD was significantly improved by T (from 4.2±3.2 to 9.3±3.7%,
p=0.01 vs. baseline), but was not affected by PL (from 4.1±2.8 to 4.0±3.4%, p=0.09 vs.
baseline). At 6 weeks the benefit in FMD was sustained in patients that received T
(9.1±3.9% vs 4.2±3.2%, p=0.01 vs. baseline; 9.1±3.9% vs 9.3±3.7%, vs 1 month, p=NS)
while no changes in FMD were observed in patients randomized to P.
In conclusion, chronic therapy with T improves endothelial function. The benefit of this
therapy seems to be sustained after discontinuation of therapy. Larger studies are
needed in order to assess the clinical implications of this scheme of therapy.
1141-195 Chromium Supplementation Shortens QTc Interval 
Duration in Patients With Type 2 Diabetes
Matjaz Vrtovec, Bojan Vrtovec, Alenka Briski, Andreja Kocijancic, Richard A. Anderson, 
Division of Endocrinology, Diabetes, and Metabolic Diseases, Ljubljana University 
Medical Center, Ljubljana, Slovenia, Nutrient Requirements and Functions Laboratory, 
Beltsville Human Nutrition Research Center, Beltsville, MD
Background. QTc interval duration is predictive of mortality in diabetic patients. Since
hromium supplementation has been shown to improve insulin sensitivity, lower plasma
insulin levels, and improve glucose homeostasis, we sought to investigate the potential
effects of chromium on QTc interval duration in patients with type 2 diabetes.
Methods. We performed a double-blind, randomized, placebo-controlled cross-over trial
enrolling 60 patients with diet-treated type 2 diabetes, who were randomly assigned to
either Group A or Group B. Group A (n=30) received 1 mg of chromium picolinate (CrPic)
daily for 12 weeks, followed by placebo in the next 12 weeks; Group B (n=30) was treated
with placebo for the first 12 weeks and CrPic in the next 12 weeks. At each visit, QT inter-
val was measured on a standard surface ECG by averaging 3 consecutive beats in leads
II, and V4, and corrected for heart rate with the Bazett formula. QTc interval shortening
was defined as a difference between two consecutive QTc interval measurements of at
least 10 ms.
Results. Baseline QTc interval was similar in both group (422±34 ms in Group A vs.
425±24 ms in Group B, p=0.77). Within first 12 weeks, QTc interval shortened in Group
A, but not in Group B, which led to a significant difference in QTc interval duration
between the groups (406±35 ms in Group A vs. 431±26 ms in Group B, p=0.01). In the
following 12 weeks, QTc interval shortened in Group B but not in Group A, which resulted
in a comparable QTc interval duration of both groups at the end of the study (414±28 ms
in Group A vs. 409±22 ms in Group B, p=0.50). Overall, QTc interval shortening (>10 ms)
with CrPic therapy was observed in 62% of patients. Except for body mass index
(31.4±4.2 kg/m2 in patients with QTc shortening vs. 28.7±4.2 kg/m2 in patients without
QTc shortening, p=0.03) none of the clinical and laboratory variables were predicitve of
QTc shortening in our patient cohort.
Conclusions. Short-term chromium supplementation shortens QTc interval duration in
patients with type 2 diabetes. These effects appear to be especially pronounced in dia-
betic patients with a higher body mass index.
1141-196 Effect of Atorvastatin and Sildenafil on Endothelial 
Function in Patients With Erectile Dysfunction and 
Increased Cardiovascular Risk
Giuseppe M. Rosano, Cristiana Vitale, Giuseppe Mercuro, Roberto Patrizi, Giuseppe 
Marazzi, Elena Cerquetani, Massimo Fini, San Raffaele Roma, Roma, Italy, University of 
Cagliari, Cagliari, Italy
Erectile Dysfunction is often associated with an increased cardiovascular risk and with a
decrease in endothelial function. In patients with increased cardiovascular risk statin
therapy reduce cardiovascular events and improves endothelial function. Oral therapy
with phosphodiesterase-5 inhibitors improves erectile function through an amelioration of
endothelial function.
Aim of the present study was to compare the effects of Sildenafil (S, 25 mg tds), Atorvas-
tatin (A, 20 mg od) and their combination (CT) on endothelium-dependent flow mediated
vasodilation (FMD), plasma nitrite, nitrate and endothelin-1 in 16 male with increased
cardiovascular risk and erectile dysfunction in a double-blinded double-crossover study.
Patients were randomized and treated for 1 weeks with either S, A or CT. Brachial artery
diameter, FMD, endothelin-1 and plasma nitrite and nitrate levels were measured at
baseline and after each treatment phase.
Brachial artery diameters remained unchanged after each treatment phase. All treat-
ments significantly improved FMD compared to baseline.
In conclusion chronic therapy with S improves endothelial function by a similar extent of
statin therapy. Combination of Sildenafil and Atorvastatin is more effective that either
therapies alone in improving endothelial function and reducing plasma levels of endothe-
lin-1 in male patients with increased cardiovascular risk.
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1141-197 Detection of Aspirin Resistance in Subjects With 
Multiple Risk Factors for Cardiovascular Disease
Alex Malinin, Malcolm Spergling, Brent Muhlestein, Steven Steinhubl, Victor Serebruany, 
Johns Hopkins University, Baltimore, MD
Background: Aspirin is known to reduce the risk of cardiovascular events by 25% in
patients with arterial vascular disease. However, the phenomena of “aspirin resistance”
may result in a higher rate of adverse outcomes in such patients. We sought to determine
the prevalence of aspirin resistance with the novel cartridge for the Ultegra Rapid Platelet
Function Analyzer (RPFA-ASA) after one dose of non-enteric coated aspirin (325-mg) in
subjects with multiple risk factors for cardiovascular disease.
Methods: Data from 148 subjects were analyzed. Platelets were assessed twice at
baseline (pre-aspirin), and after 2-30 hours (post-aspirin). Aspirin response units (ARU)
stimulated by cationic propyl gallate were measure by Ultegra RPFA-ASA, while 5µM epi-
nephrine-induced conventional aggregometry was used as a reference.
Results: A single dose of aspirin decreases ARU from 647±95 to 436±69, matching
closely the diminished aggregation from 72±21% to 25±10%. Figure 1 demonstrates the
ranges of responses in ARU’s for patients prior and after aspirin ingestion. There is an
area of overlap where both pre-ASA and post-ASA measurements fall, and it is not possi-
ble to assay with any assurance that platelet function has been effectively suppressed by
the ASA, regardless of the test result prior to therapy. The use of the equivocal (yellow)
zone increases the reliability of a posteriori assignment of a patient into an effectiveness
group, since it refuses to supply a decision in cases where there is high variability in the
decision. The range of 550 and above as a non-responder, 500 to 550 as the equivocal
zone, and less than than 550 as an aspirin responder results in the optimal boundaries to
minimize the errors-of-classification.
Conclusion: The timely detection of aspirin resistance is critical for adequate manage-
ment of antithrombotic regimens. The Ultegra RPFA-ASA is a novel, fast method that
could be used in clinical practice for monitoring of aspirin efficacy, and early detection of
aspirin resistance.
1141-198 Etoricoxib Has No Adverse Effects on Biomarkers of 
Cardiovascular Risk in Patients With Osteoarthritis
Peter M. DiBattiste, Cong Chen, John Viscusi, Sean P. Curtis, Christopher P. Cannon, 
Merck Research Laboratories, Blue Bell, PA, Brigham and Women's Hospital, Boston, 
MA
BACKGROUND:Selective cyclooxygenase-2 (COX-2) inhibitors are effective anti-inflam-
matory agents, and their use results in a lower rate of ulcers and their complications com-
pared to non-selective NSAIDs. However, questions have been raised about a possible
adverse effect on CV outcomes.
METHODS: 433 patients with osteoarthritis were randomized (double-blind) to etoricoxib
90 mg qd, celecoxib 200 mg bid, ibuprofen 800 mg tid, or placebo for 12 weeks. LDL cho-
lesterol, homocysteine, fibrinogen, and CRP were measured at baseline, and at 6 and 12
weeks. The primary hypothesis was that etoricoxib is non-inferior to placebo in its effect
on all four biomarkers based on an “on-treatment” analysis. Non-inferiority margins (20%
for LDL, fibrinogen and homocysteine, and 80% for CRP) were pre-defined for each
biomarker based on published data. RESULTS: Etoricoxib was non-inferior to placebo on
all four biomarkers after 12 weeks (Table). Etoricoxib was also non-inferior to celecoxib
and ibuprofen. The effect of etoricoxib on CRP was greater in patients who smoked (46%
reduction vs placebo), with diabetes (51%) or with higher Framingham CV risk score
(32%).
CONCLUSION: Etoricoxib was comparable to placebo, celecoxib, and ibuprofen in its
effect on four established biomarkers of CV risk. While clinical outcomes data will provide
a more definitive CV safety profile for COX-2 inhibitors, these data provide reassurance
that selective COX-2 inhibition does not have an adverse effect on these known markers
of CV risk. 
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1142-177 Antecedent Hypertension and the Risk of Subsequent 
Left Ventricular Remodeling After Acute Myocardial 
Infarction: Insights From the Survival and Ventricular 
Enlargement Trial
Satish Kenchaiah, Marc A. Pfeffer, Martin St. John Sutton, Ted Plappert, Jean-Lucien 
Rouleau, Gervasio A. Lamas, Zion Sasson, John O. Parker, Edward M. Geltman, Eugene 
Braunwald, Scott D. Solomon, Brigham and Women's Hospital, Boston, MA
Background: While hypertension increases the risk of myocardial infarction (MI),
whether antecedent hypertension influences the risk of subsequent left ventricular (LV)
enlargement in survivors of an acute MI with LV systolic dysfunction is unclear.
Methods: We assessed echocardiographic evidence of ventricular remodeling between
baseline (mean±SD, 11±3 days) and 2 years after acute MI in 122 hypertensive (defined
as history of treated hypertension, or baseline systolic BP >140, or diastolic BP >90 mm
Hg) and 334 nonhypertensive participants of the Survival and Ventricular Enlargement
(SAVE) echo substudy.
Results: As compared with nonhypertensives, the baseline heart size, defined as the
sum of the average short and long axis LV cavity areas (LVCA), was similar (70.1±11.9
vs. 68.8±11.2 cm2, p=0.33 at end diastole; 50.1±11.3 vs. 48.8±10.8 cm2, p=0.31 at end
systole), but short axis LV myocardial area (LVMA, 24.7±4.3 vs. 25.7±5.0 cm2, p=0.043)
and wall thickness (LVWT, 1.15 ±0.16 vs. 1.21±0.17 cm, p=0.004) were higher among
hypertensives. The infarct segment lengths were similar in the two groups (p=0.22).
Whereas end-diastolic and end-systolic LVCA increased significantly in both groups from
baseline to 2 years (p <0.001), the increase was significantly greater in hypertensives as
compared with nonhypertensives (+5.6±11.5 vs. +2.2±10.7 cm2, p=0.005 at end diastole;
+6.23±12.75 vs. +2.94±11.4 cm2, p=0.012 at end systole). There was no concomitant
difference in change in LVMA or LVWT between the two groups (p>0.30). After adjusting
for study medication (captopril), age, body mass index, peak creatine kinase, diabetes,
smoking, prior MI, infarct size and location; antecedent hypertension was associated with
a doubling of the risk of LV dilatation, defined as an increase of >1.96 times SDs of mea-
surement reproducibility of end-diastolic or end-systolic LVCA (50.8% vs. 37.7%, OR
2.02, 95% CI 1.23-3.31, p=0.006). There was no effect modification of this association by
diabetes, infarct size, or captopril use (all p-values for interaction >0.10).
Conclusions: Antecedent hypertension is associated with an increased risk of LV
enlargement in survivors of an acute MI with LV systolic dysfunction.
1142-178 The G1675A Gene Polymorphism of the Angiotensin II 
Type 2-Receptor Gene Influences Cardiac Structural 
Response to Antihypertensive Therapy
Markus P. Schneider, Arnfried U. Klingbeil, Karl F. Hilgers, Malte Ludwig, Rainer Kolloch, 
Klaus O. Stumpe, Roland E. Schmieder, University of Erlangen-Nuremberg, Erlangen-
Nuremberg, Germany, University of Bonn, Bonn, Germany
Introduction: In vitro, the angiotensin II type 2 receptor (AT2-R) exerts antiproliferative
effects in the cardiovascular system. Moreover, the G1675A gene polymorphism of the
AT2-R has been shown to influence left ventricular structure in essential hypertensive
subjects. We hypothesized that this gene polymorphism may also alter the cardiac struc-
tural response to antihypertensive therapy, in particular to agents interfering with the
renin-angiotensin-system.
Methods: In the Cardiovascular Irbesartan Project (CVIP), a double blind randomized
clinical study, patients with mild-to-moderate essential hypertension and early target
organ damage as evidenced by an increased intima media thickness (IMT) of the com-
mon carotid artery (0.8-1.5 mm) were treated with either irbesartan or atenolol for 18
months. The G1675A genotype of the AT2-R gene was determined by a 5’ nuclease
allelic discrimination assay using real-time PCR in 112 subjects.
Results: At baseline, blood pressure and left ventricular mass index (LVMI) were similar
between genotypes. In addition, after 6 and after 18 months, blood pressure control was
similar between genotypes. However, G allele carriers (males with G genotype and
females with GG or GA genotype, n=62) showed an increase in LVMI while hemizygous
males and females with the AA genotype (n=50) showed a decrease in LVMI (+2.5±20.4
vs -8.8±25.0 g/m2, p=0.02 after 6 months and +6.6±26.3 vs -11.4±21.9 g/m2,, p=0.002
after 18 months). These differences were also observed in both treatment subgroups to a
similar extent.
Conclusion: The A allele of the G1675A polymorphism of the AT2-R was associated
with a favorable response of cardiac structure to antihypertensive therapy, regardless of
the type of treatment.
Effect of Atorvastatin, Sildenafil and Their Combination on Endothelial Function
Baseline S A CT
Brachial artery (mm) 4.37±0.4 4.38±0.3; 4.37±0.2 4.38±0.4
FMD (%) 6.8±0.9 10.97±0.7* 11.2±0.6* 12.5±0.9**
Nitrite+nitrate (Nox) 41.3±10.6 49.3±6.7* 48.7±7.3* 52.3±9.7**
Endothelin-1(pg/ml) 3.3±0.5 2.8±0.7* 2.4±0.6** 2.4±0.8**
*=p<0.05 **=p<0.01
